What Avet Pharmaceuticals does

Avet Pharmaceuticals Inc. is a privately held specialty generic pharmaceutical company founded in 2006 and headquartered in East Brunswick, New Jersey. Formerly known as Heritage Pharmaceuticals Inc., Avet develops, manufactures, and markets a portfolio of more than 150 generic and legacy branded pharmaceutical products across oral solids, liquids, and injectables, spanning therapeutic categories that include oncology, cardiovascular, metabolic disease, anti-infective, and pain management. The company targets the U.S. prescription drug market, supplying wholesalers, distributors, hospitals, surgical centers, and pharmacies, and it differentiates through affordable access to AB-rated generic equivalents, including the April 2022 launch of Propofol Injectable Emulsion USP to address a market shortage. Avet's commercial operations are led by a dedicated U.S. field sales and business development team, with Chief Commercial Officer Dan Lukasiewicz overseeing sales, marketing, and partnership activity.

Avet's core technology is hybrid specialty generic pharmaceutical development and manufacturing. The company operates U.S. based manufacturing and packaging facilities in East Brunswick, NJ (Avet Pharmaceuticals Labs Inc.), supplemented by offshore manufacturing and operations support at Avet Lifesciences Private Limited in Pune, India. Product development and additional manufacturing capacity are strategically outsourced to U.S. FDA approved partner organizations across North America, Europe, and Asia, creating a globally integrated supply network that the company cites as a key operational asset. The company pursues continuous portfolio expansion through a dedicated business development function focused on product acquisitions, licensing arrangements, and strategic partnerships.

Avet generates revenue primarily through sale of FDA-approved generic and legacy branded pharmaceutical products to U.S. healthcare intermediaries, with secondary revenue exposure to licensing and partnership arrangements. Pricing is contractually negotiated through wholesalers, distributors, and pharmacy benefit managers rather than publicly disclosed. The company has no publicly listed equity, no disclosed venture or institutional funding rounds, and was historically affiliated with Emcure Pharmaceuticals Ltd. as its former parent. Operations are governed by U.S. FDA regulatory standards, and Avet resolved the multi-year Generic Pharmaceuticals Pricing Antitrust Litigation in 2024 through three separate $10 million settlements with Direct Purchaser Plaintiffs, End Payer Plaintiffs, and State Attorneys General.

Name

Avet Pharmaceuticals

Legal name

Avet Pharmaceuticals Inc.

Website

https://avetpharma.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Avet Pharmaceuticals is a privately held specialty generic pharmaceutical company that develops, manufactures, and sells 150+ FDA-approved generic and legacy branded products across oral solids, liquids, and injectables, supplying U.S. wholesalers, hospitals, and pharmacies across multiple therapeutic categories.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Generic pharmaceuticals
• Prescription drug manufacturing
• Injectable formulations
• Oral solid dosage
• Generic drug development

Headquarters

HQ city

East Brunswick

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Products Sales: Sale of FDA-approved generic pharmaceutical products including oral solids, liquids, and injectables across multiple therapeutic categories including oncology, cardiovascular, metabolic disease, anti-infective, and pain management. Revenue generated through direct sales to wholesalers, distributors, and healthcare providers in the US prescription drug market.
2. Product Acquisitions and Licensing: Avet actively seeks opportunities for product acquisitions, licenses, and partnerships across product development, manufacturing, sales, and marketing. The company collaborates with potential partners to create strategic solutions that enhance value and profitability through licensing arrangements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Avet Pharmaceuticals is a specialty generic pharmaceutical company that develops, manufactures, and sells FDA-approved generic and legacy branded pharmaceutical products for the U.S. prescription drug market. The company offers a diversified portfolio of over 150 products spanning oral solids, liquids, and complex injectables across therapeutic categories including oncology, cardiovascular, metabolic disease, anti-infective, and pain management, supported by U.S.-based manufacturing and a globally integrated supply network of FDA-approved partner organizations.

Product overview

Avet Pharmaceuticals is a specialty generic pharmaceutical company that offers a diversified portfolio of generic pharmaceutical products for the US prescription drug market. The company's product portfolio comprises over 150 products spanning multiple dosage forms, including Oral Solids and Liquids (tablets, capsules, and liquids) and Injectables (high-precision formulations for rapid and effective delivery). The products cover several therapeutic categories including oncology, cardiovascular, metabolic disease, anti-infective, and pain management. Avet Pharma specializes in acquiring, developing, and selling generic pharmaceutical products through its global network of manufacturing and scientific excellence.

Differentiator

Problem solved

Functional benefit

Products and services

• Oral Solids and Liquids A range of oral solid and liquid generic pharmaceutical products spanning multiple therapeutic categories, including tablets, capsules, and liquids, for healthcare providers and the U.S. prescription drug market.
• Injectables High-precision injectable generic pharmaceutical formulations designed for rapid and effective delivery, with an extensive range of formulations tailored to meet diverse therapeutic needs across multiple therapeutic categories.
• Propofol Injectable Emulsion, USP Propofol Injectable Emulsion, USP 10 mg/mL in 20, 50 and 100 mL Single Patient-Use Vials; an AB-rated generic equivalent of DIPRIVAN (propofol) Injectable Emulsion USP indicated for initiation and maintenance of Monitored Anesthesia Care (MAC) sedation, combined sedation and regional anesthesia, induction and maintenance of general anesthesia, and ICU sedation of intubated, mechanically ventilated patients. Launched to address a market shortage in hospitals and surgical centers.

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered legacy, core and minor.

• Emcure Pharmaceuticals Ltd.legacyOthersAvet's former parent company. The settlement with State AG Plaintiffs resolves claims against both Avet and Emcure Pharmaceuticals Ltd. as Avet's former parent company. Historical relationship established when company was formerly known as Heritage Pharmaceuticals Inc.
• Dispensary of HopecoreStrategic or Co-development PartnerAvet makes annual pharmaceutical product donations to the Dispensary of Hope, which distributes life-saving pharmaceuticals to low-income, chronically ill patients. This partnership supports Avet's mission to provide affordable and accessible medicines.
• Brother's Brother FoundationcoreStrategic or Co-development PartnerAvet donates pharmaceutical products to Brother's Brother Foundation, which collects donated pharmaceuticals and distributes them to local hospitals, clinics, HIV/AIDS facilities, homes for the elderly, and homes for orphaned and abandoned children around the globe.
• Sister2SisterminorStrategic or Co-development PartnerLocal nonprofit partnership supporting minority and underserved breast cancer survivors. Avet team participates in their annual walk-a-thon to raise funds for this important cause.
• Middlesex County REPLENISHminorStrategic or Co-development PartnerPartnership with Middlesex County's REPLENISH organization for food drives. Avet participated in the Nourishing Neighbors '30 for 30' Challenge and collected 600 lbs. of food and hygiene products through employee contributions.
• Dress for SuccessminorStrategic or Co-development PartnerAvet team organized a clothing drive for Dress for Success, which supports over 22,000 women in Northern New Jersey by providing training and professional attire to boost confidence and help women pursue brighter futures.
• FDA Approved Manufacturing Partners (North America, Europe, Asia)coreStrategic or Co-development PartnerAvet has strategically outsourced product development and manufacturing to U.S. FDA approved partner organizations in North America, Europe, and Asia. This globally integrated supply network provides access to cost-effective development, materials, and manufacturing capacity.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Others

• Emcure Pharmaceuticals: India-based pharmaceutical manufacturer and Avet's former parent company. Emcure was released from antitrust litigation claims against Avet in the 2024 settlements, making it a former affiliate and a relevant comparator for Avet's manufacturing footprint and Indian API sourcing model.

Emerging players

• Aurobindo Pharma: India-based vertically integrated generic pharmaceutical manufacturer with substantial US generic presence. Aurobindo's vertically integrated model and broad US portfolio place it as both a peer and a potential contract development partner to Avet given the company's reliance on FDA-approved Indian manufacturers.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company and a major US generic player following the Taro Pharmaceutical acquisition. Sun Pharma competes with Avet across US generics, with particular strength in specialty formulations and sterile injectables.

Direct peers

• Lannett Company: US-focused specialty generic pharmaceutical manufacturer with a portfolio of oral solids, liquids, and injectables. Lannett's therapeutic mix and US distribution model closely parallel Avet's, making it a highly relevant size-comparable peer.
• Apotex: Largest Canadian-based generic pharmaceutical manufacturer and a privately held company like Avet. Apotex competes directly with Avet in US generic oral solids and injectables, with similar business model focus on affordable, high-quality generic medicines across multiple therapeutic categories.
• Alvogen: Privately held US-focused specialty generic pharmaceutical company with a portfolio spanning multiple therapeutic categories and dosage forms including injectables. Alvogen's size, US-centric focus, and broad specialty generic portfolio closely mirror Avet's positioning.

Broad incumbents

• Sandoz: Spun off from Novartis in 2023 as a standalone generics and biosimilars leader. Sandoz competes head-to-head with Avet across the US generic prescription drug market and has a far broader portfolio, deeper capital base, and global manufacturing footprint.
• Endo International: Specialty pharmaceutical company with significant generics and sterile injectable manufacturing capabilities through its Par Pharmaceutical business. Endo competes with Avet in complex injectables and specialty generics distributed through US hospital and pharmacy channels.
• Teva Pharmaceutical Industries: The world's largest generic pharmaceutical manufacturer and Avet's former CEO George Svokos's longtime employer. Teva competes directly with Avet in US oral solids and injectables across the same therapeutic categories, but operates at vastly greater scale and with proprietary R&D.
• Viatris: Formed through the Mylan-Upjohn combination, Viatris is one of the largest US generic pharmaceutical manufacturers with a broad specialty and generics portfolio. Viatris competes with Avet across therapeutic categories including cardiovascular, oncology, and infectious disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/avet-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avet Pharmaceuticals